Dr. Changhao Bi received his doctoral degree in Microbiology and Cell Science from the University of Florida. He had completed postdoctoral research at the University of Delaware and at The Joint BioEnergy Institute (JBEI), Lawrence Berkeley National Laboratory. Dr. Bi is currently a Principal Investigator and Professor at the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences. Dr. Bi’s research focuses on developing of cellular bio-factories by metabolically engineering bacterial strains. Recently his focus has been to develop and optimize CRISPR based systems. Such developments include an electroporation-based CRISPR system and a gRNA-free CRISPR system for PAM-free/CRISPR-tolerant gene regions. Both have applications to develop bioengineered strains. From these cellular bio-factories, Dr. Bi aims to create products including chemical feedstock, biofuels, and natural medical products.
Research Area and Skills
Recognize this scientist’s Expertise for their contribution in your research
Biological Engineering 2 CRISPR / Cas9 3 DNA Extraction 0 DNA Purification 0 Gene Editing 1 Gene Knock-In 1 Gene Knock-Out 1 Microbial Biotechnology 0 Molecular Cloning 1
This guy hasn’t posted anything yet.
Hot Posts for You
The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More
The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More
IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More
"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More
In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More
The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More
Zhao, D., Li, J., Li, S., Xin, X., Hu, M., Price, M. A., ... & Zhang, X. (2020). Glycosylase base editors enable C-to-A and C-to-G base changes. Nature Biotechnology.
Li, Z., Xiong, B., Liu, L., Li, S., Xin, X., Li, Z., Zhang, X, Bi, C. (2019). Development of an autotrophic fermentation technique for the production of fatty acids using an engineered Ralstonia eutropha cell factory. Journal of industrial microbiology & biotechnology, 1-8.
Feng, X., Zhao, D., Zhang, X., Ding, X., Bi, C. (2018). CRISPR/Cas9 assisted Multiplex Genome Editing Technique in Escherichia coli. Biotechnology journal, 1700604.
Zhao, D., Feng, X., Zhu, X., Wu, T., Zhang, X., Bi, C. (2017). CRISPR/Cas9-assisted gRNA-free one-step genome editing with no sequence limitations and improved targeting efficiency. Scientific Reports, 16624.
This guy has no following anyone.
Popular Cloud Scientists